Madrigal Pharmaceuticals poised for market dominance with Rezdiffra’s first full quarter… EP News Bureau Aug 12, 2024 As per the GlobalData report, as Rezdiffra secures its position as a first-line treatment for MASH, Madrigal Pharmaceuticals eyes…
Madrigal’s efforts for resmetirom will set tone for future launches of NASH therapies: GlobalData EP News Bureau Dec 7, 2023 In December 2022, the company successfully concluded raising a total of $309 million following positive topline data from the…
